centres-of-excellence-clinical-research-centre-beacon-hospital-malaysia

PUSAT PENELITIAN UJI KLINIS

Pusat Penelitian Uji Klinis Beacon Hospital didirikan pada tahun 2016. Kemudian pada tahun 2020, pusat penelitian klinis ini telah menjadi salah satu Pusat Keunggulan kami dengan tujuan membuat kami menjadi rumah sakit dengan integritas dan perilaku etika terpercaya secara global untuk penelitian klinis.

Uji klinis dan studi penelitian merupakan komponen kunci dari pendekatan penelitian berdasarkan bukti di Pusat Penelitian Klinis Beacon Hospital.

Dengan upaya kolektif yang dilakukan oleh pasien, tim spesialis onkologi, dan tim penelitian klinis kami, kami telah berkontribusi pada banyak uji klinis dan jumlah obat onkologi yang diluncurkan di Malaysia sangat mengesankan. Ini dengan bangga membuat kami menjadi salah satu situs uji klinis teratas di Malaysia pada tahun 2021 di bidang onkologi, menurut laporan resmi dari Clinical Research Malaysia (CRM).

Jika Anda tertarik dan ingin tahu lebih banyak tentang uji coba ini yang sedang berlangsung, silakan hubungi kami di +603-7787 2854 atau Anda dapat mengirimkan email ke clinicalresearch@beaconhospital.com.my.

Mengapa Memilih Kami

Sejalan dengan fokus jangka panjang Pemerintah Malaysia untuk menjadikan negara sebagai pemain klinis penelitian yang signifikan secara global, kami berkomitmen untuk menemukan cara yang lebih baik untuk mengobati kanker dan membantu pasien kanker.

Selain fakta bahwa semua studi klinis kami telah mendapatkan persetujuan dari Komite Etik Medis dan Penelitian Kementerian Kesehatan Malaysia, kami juga mematuhi standar Praktik Klinis yang Baik (GCP) lokal dan internasional untuk menjaga kepentingan etis pasien uji coba.

Uji Coba Klinis yang Sedang Berlangsung

Hingga saat ini, tim onkologi kami telah berpartisipasi dalam banyak uji coba klinis, termasuk dalam membandingkan efektivitas perawatan kemoterapi yang berbeda; resistensi terhadap inhibitor; perubahan epigenetik pada kanker nasofaring; dan pengobatan untuk adenokarsinoma gastroesofageal lanjut atau metastatik, antara lain.

Kanker Paru - Paru

No. Clinical Trial Status
1 ATORG 001
A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).		 Aktif (Perekrutan)
2 ATORG003
A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation.		 Aktif (Perekrutan)
3 ATORG004
Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer.		 Aktif (Perekrutan)
4 InCyte Podium (INCMGA0012-304)
A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304).
 Aktif (Perekrutan)
5 ML41262
A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine.		 Aktif (Perekrutan)
6 PFIZER A7471067
Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review.
 Aktif (Perekrutan)
7 MARIPOSA2
A phase 3, Open-Label, Randomised Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic NSCLC After Osimertinib Failure.
 Aktif (Perekrutan)
8 Pacific 8
A Phase 3, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy.
 Aktif (Perekrutan)
9 Adaura 2
A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection.		 Aktif (Perekrutan)
10 MK7684A-002
A Phase 2, Multi-Center, Randomised study to compare the efficacy and safety of MK-7684-A or MK-7684-A Plus Docetaxel versus Docetaxel Monotherapy in the treatment of participants with Metastatic NSCLC with progressive disease after treatment with a Platinum Doublet Chemo or Immunotherapy.		 Aktif (Tidak diperlukan lagi)
11 LAURA
A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive on-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA).
 Aktif (Tidak diperlukan lagi)
12 MARIPOSA
A Randomized Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.		 Aktif (Tidak diperlukan lagi)
13 MS200095-0031-INSIGHT 2
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET 1amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior Osimertinib therapy.		 Aktif (Tidak diperlukan lagi)
14 CT-P16 3.1
A double-blind, randomized, active-controlled, parallel-Group, Phase 3 study to compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.		 Aktif (Tidak diperlukan lagi)
15 MK7902-007
A Phase III, randomized, double-blind trial of Pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007).		 Aktif (Tidak diperlukan lagi)
16 KontRASt-02
Study of JDQ443 in Comparison With Docetaxel in Participants with Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer		 TERBARU! (Segera Dibuka)
17 PALOMA 3
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy		 TERBARU! (Segera Dibuka)
18 PALOMA 2
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.		 TERBARU! (Segera Dibuka)
19 MK3475-D46
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK‑3475) in Combination with Sacituzumab Govitecan Versus MK‑3475 Monotherapy as First-line Treatment in Participants With PD-L1 Positive Advanced Non-small Cell Lung Cancer (KEYNOTE-D46/EVOKE-03).		 TERBARU! (Segera Dibuka)
20 MK3475-042
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042).		 SUDAH LENGKAP
21 EMR200095-006
Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor.		 SUDAH LENGKAP
22 A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors. SUDAH LENGKAP

Kanker Payudara

No. Clinical Trial Status
1 EPIK-B3
A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer (TNBC) with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.		 Aktif (Perekrutan)
2 EPIK-B2
A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation.		 Aktif (Perekrutan)
3 Lidera 
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.		 Aktif (Perekrutan)
4 CAPITELLO-292
A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer.
 TERBARU! (Segera Dibuka)
5 TROIKA
A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer.		 SUDAH LENGKAP
6 CLEE011A2404
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease.
 SUDAH LENGKAP
7 Healthcare Performance Measurement and Reporting For Breast Cancer Services In Malaysia SUDAH LENGKAP

(View Abstract)
(View Paper)

Kanker Usus Besar

No. Clinical Trial Status
1 Krystal 10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation.		 Aktif (Perekrutan)
2 61186372GIC2002
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer.		 Aktif (Perekrutan)
3 MK-4280A-007
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer metastatic colorectal adenocarcinoma whose tumors are positive for PD-L1 CPS≥1, have pMMR status based on IHC testing at screening have progressed on or could not tolerate prior line(s) of therapy.		 Aktif (Perekrutan)

Lain-Lain

No. Clinical Trial Status
1 MO42541- IMBRAVE251
A Phase III, open-label, randomised study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib alone in hepatocellular carcinoma previously treated with atezolizumab and bevacizumab.		 Aktif (Perekrutan)
2 MK3475-394
A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma.		 Aktif (Tidak diperlukan lagi)
3 Invitrocue PDO for drug screening
Validating the use of patient-derived organoids for predicting drug response to chemotherapy in patients with advanced solid cancers.		 Aktif (Tidak diperlukan lagi)
4 BTM ASEAN
Bone turnover markers reference database in five
South East Asia Countries.
 SUDAH LENGKAP
5 Keynote-590
A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5FU versus placebo in combination with cisplatin and 5FU as first-line treatment in subjects with advanced/metastatic esophageal carcinoma.		 SUDAH LENGKAP
6 Tessa FF01
A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC.
 SUDAH LENGKAP
7 Hyperthermia – REMISSION 1C
Hyperthermia in Treating Patients with Unresectable Abdominal, Pelvic tumours and Cutaneous and Peritoneal Metastases.
 SUDAH LENGKAP
8 Studies On Epigenetic Changes in Nasopharyngeal Cancer.
 SUDAH LENGKAP
9 Healthcare Performance Measurement and Reporting System (HPMRS) For Cancer Care. SUDAH LENGKAP
10 A Randomized, Phase II, Placebo Controlled Study of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma. SUDAH LENGKAP
11 An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC).
 SUDAH LENGKAP

Terlepas dari uji klinis onkologi, konsultan kami dari pusat keunggulan lain juga telah memberikan kontribusi besar untuk spesialisasi klinis mereka dengan penelitian yang dilakukan serta dipublikasikan.
Di bawah ini adalah publikasi penelitian (abstrak, makalah penelitian, presentasi poster, dan lainnya ) yang dihasilkan oleh konsultan kami:

No.

Judul Publikasi

Name Konsultan

Jenis Presentasi

1

Sistem Pengukuran dan Pelaporan Kinerja Kesehatan (HPMRS) untuk Perawatan Kanker

2

Pengukuran dan Pelaporan Kinerja Layanan Kesehatan untuk Pelayanan Perawatan Kanker Payudara di Malaysia

3

Apakah betul jika sebuah Lukisan menggambarkan seribu makna?. Berikut adalah Sebuah Studi tentang Kualitas Teknis Foto Klinis Okulofasial Estetika Online

Dr Ong Chin Tuan
(Consultant Ophthalmologist)

4

Kelangsungan Hidup bagi Penderita kanker payudara di Pusat Spesialis Asia dari Malaysia: Menurut Analisis Retrospektif

Dato Ibrahim
Dr Azura
Arkonam Balasubramaniam Manivannan (Consultant Oncologists)
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)

5

Memberikan keluhan pasien dan pola rujukan perawatan paliatif

Dr Felicia Chang
Dr Azura
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)

6

KASRP
Penilaian terhadap pola tingkah laku para perawat terhadap program pendidikan digital dan manajemen nyeri di
rumah sakit Malaysia. (penjelasan Manajemen nyeri adalah mengidentifikasi dan mengelola pengalaman sensorik
atau emosional yang berkaitan dengan kerusakan jaringan atau fungsional dengan onset mendadak atau lambat dan
berintensitas ringan hingga berat dan konstan)

Dr Koon Sim Lan
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)

7

Analisis Retrospektif Hasil Klinis Radioterapi Stereotaktik Tubuh pada Kanker Prostat Lokal di sebuah Pusat Spesialis Kanker Asia.

Jasmin Loh Pei Yuin,
Jessica Tan Jia Shin,
Chen Bao Jing,
Tho Lye Mun,
Manivanna Arkonam Balasubramaniam,
Dato Mohamed Ibrahim Wahid

8

Obat antiinflamasi nonsteroid topikal untuk manajemen nyeri osteoartritis: Rekomendasi konsensus

Joon-Kiong Lee,
Azlina A.Abbas,
Tien-Eang Cheah,
Ruslan Nazaruddin Simanjuntak,
Sargunan Sockalingam,
Sharifah Roohi

Jika anda tertarik dan ingin mengetahui lebih lanjut mengenai uji coba klinis yang sedang berlangsung, silahkan hubungi kami di  +603-7787 2854 atau anda dapat mengirim email pada kami di clinicalresearch@beaconhospital.com.my.

Tampilkan berdasarkan keahlian

Tampilan selanjutnya